AGN-210669 ophthalmic solution, 0.05%

DRUG2 trials

Sponsors

Allergan

Conditions

GlaucomaGlaucoma, Open-AngleOcular Hypertension

Phase 1

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

CompletedNCT00809848

AllerganGlaucoma, Ocular Hypertension

Start: 2009-02-28End: 2009-05-31Updated: 2013-10-18

Phase 2

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

CompletedNCT01001195

AllerganGlaucoma, Open-Angle, Ocular Hypertension

Start: 2009-11-30End: 2010-04-30Updated: 2013-10-18